The Brawl Taking Shape Over Pfizer's Multibillion-Dollar Heart Monopoly -- Heard on the Street -- WSJ
Here's How Much You Would Have Made Owning Alnylam Pharmaceuticals Stock In The Last 10 Years
Cantor Fitzgerald Reiterates Neutral on Alnylam Pharmaceuticals, Maintains $220 Price Target
Alnylam Pharmaceuticals, Inc. (ALNY): Do Hedge Funds Recommend This Biotech Stock Now?
Evercore Maintains Alnylam Pharmaceuticals(ALNY.US) With Buy Rating, Maintains Target Price $260
Evercore analyst Liisa Bayko maintains $Alnylam Pharmaceuticals(ALNY.US)$ with a buy rating, and maintains the target price at $260.According to TipRanks data, the analyst has a success rate of 45.7%
RBC Capital Maintains Alnylam Pharmaceuticals(ALNY.US) With Buy Rating, Maintains Target Price $300
RBC Capital analyst Luca Issi maintains $Alnylam Pharmaceuticals(ALNY.US)$ with a buy rating, and maintains the target price at $300.According to TipRanks data, the analyst has a success rate of 22.2%